Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 219

1.

An evaluation of the role of properdin in alternative pathway activation on Neisseria meningitidis and Neisseria gonorrhoeae.

Agarwal S, Ferreira VP, Cortes C, Pangburn MK, Rice PA, Ram S.

J Immunol. 2010 Jul 1;185(1):507-16. doi: 10.4049/jimmunol.0903598. Epub 2010 Jun 7.

2.

Native polymeric forms of properdin selectively bind to targets and promote activation of the alternative pathway of complement.

Ferreira VP, Cortes C, Pangburn MK.

Immunobiology. 2010 Nov;215(11):932-40. doi: 10.1016/j.imbio.2010.02.002. Epub 2010 Feb 12.

3.

Mesenchymal stem cells inhibit complement activation by secreting factor H.

Tu Z, Li Q, Bu H, Lin F.

Stem Cells Dev. 2010 Nov;19(11):1803-9. doi: 10.1089/scd.2009.0418. Epub 2010 Aug 1.

4.

Review of meningococcal group B vaccines.

Granoff DM.

Clin Infect Dis. 2010 Mar 1;50 Suppl 2:S54-65. doi: 10.1086/648966. Review.

5.
6.

Annexin-II, DNA, and histones serve as factor H ligands on the surface of apoptotic cells.

Leffler J, Herbert AP, Norström E, Schmidt CQ, Barlow PN, Blom AM, Martin M.

J Biol Chem. 2010 Feb 5;285(6):3766-76. doi: 10.1074/jbc.M109.045427. Epub 2009 Dec 1.

7.

Properdin: emerging roles of a pattern-recognition molecule.

Kemper C, Atkinson JP, Hourcade DE.

Annu Rev Immunol. 2010;28:131-55. doi: 10.1146/annurev-immunol-030409-101250. Review.

PMID:
19947883
8.

Factor H in porcine seminal plasma protects sperm against complement attack in genital tracts.

Sakaue T, Takeuchi K, Maeda T, Yamamoto Y, Nishi K, Ohkubo I.

J Biol Chem. 2010 Jan 15;285(3):2184-92. doi: 10.1074/jbc.M109.063495. Epub 2009 Nov 17.

9.

Serum resistance of Acinetobacter baumannii through the binding of factor H to outer membrane proteins.

Kim SW, Choi CH, Moon DC, Jin JS, Lee JH, Shin JH, Kim JM, Lee YC, Seol SY, Cho DT, Lee JC.

FEMS Microbiol Lett. 2009 Dec;301(2):224-31. doi: 10.1111/j.1574-6968.2009.01820.x. Epub 2009 Oct 13.

10.

Severe atypical HUS caused by CFH S1191L--case presentation and review of treatment options.

De S, Waters AM, Segal AO, Trautmann A, Harvey EA, Licht C.

Pediatr Nephrol. 2010 Jan;25(1):97-104. doi: 10.1007/s00467-009-1306-7. Epub 2009 Oct 24.

PMID:
19856002
11.

Maintenance of kidney function following treatment with eculizumab and discontinuation of plasma exchange after a third kidney transplant for atypical hemolytic uremic syndrome associated with a CFH mutation.

Davin JC, Gracchi V, Bouts A, Groothoff J, Strain L, Goodship T.

Am J Kidney Dis. 2010 Apr;55(4):708-11. doi: 10.1053/j.ajkd.2009.08.011. Epub 2009 Oct 25.

PMID:
19854549
12.

Complement factor H binds at two independent sites to C-reactive protein in acute phase concentrations.

Okemefuna AI, Nan R, Miller A, Gor J, Perkins SJ.

J Biol Chem. 2010 Jan 8;285(2):1053-65. doi: 10.1074/jbc.M109.044529. Epub 2009 Oct 22.

13.

Immune evasion of the human pathogenic yeast Candida albicans: Pra1 is a Factor H, FHL-1 and plasminogen binding surface protein.

Luo S, Poltermann S, Kunert A, Rupp S, Zipfel PF.

Mol Immunol. 2009 Dec;47(2-3):541-50. doi: 10.1016/j.molimm.2009.07.017. Epub 2009 Oct 21.

PMID:
19850343
14.

Complement factor H is expressed in adipose tissue in association with insulin resistance.

Moreno-Navarrete JM, Martínez-Barricarte R, Catalán V, Sabater M, Gómez-Ambrosi J, Ortega FJ, Ricart W, Blüher M, Frühbeck G, Rodríguez de Cordoba S, Fernández-Real JM.

Diabetes. 2010 Jan;59(1):200-9. doi: 10.2337/db09-0700. Epub 2009 Oct 15.

15.

Targeted inhibition of the complement alternative pathway with complement receptor 2 and factor H attenuates collagen antibody-induced arthritis in mice.

Banda NK, Levitt B, Glogowska MJ, Thurman JM, Takahashi K, Stahl GL, Tomlinson S, Arend WP, Holers VM.

J Immunol. 2009 Nov 1;183(9):5928-37. doi: 10.4049/jimmunol.0901826. Epub 2009 Oct 14.

16.

Recent developments in low molecular weight complement inhibitors.

Qu H, Ricklin D, Lambris JD.

Mol Immunol. 2009 Dec;47(2-3):185-95. doi: 10.1016/j.molimm.2009.08.032. Epub 2009 Oct 2. Review.

17.

Platelet-associated complement factor H in healthy persons and patients with atypical HUS.

Licht C, Pluthero FG, Li L, Christensen H, Habbig S, Hoppe B, Geary DF, Zipfel PF, Kahr WH.

Blood. 2009 Nov 12;114(20):4538-45. doi: 10.1182/blood-2009-03-205096. Epub 2009 Aug 24.

18.

Functional analyses indicate a pathogenic role of factor H autoantibodies in atypical haemolytic uraemic syndrome.

Strobel S, Hoyer PF, Mache CJ, Sulyok E, Liu WS, Richter H, Oppermann M, Zipfel PF, Józsi M.

Nephrol Dial Transplant. 2010 Jan;25(1):136-44. doi: 10.1093/ndt/gfp388. Epub 2009 Aug 7.

PMID:
19666655
19.

The disease-protective complement factor H allotypic variant Ile62 shows increased binding affinity for C3b and enhanced cofactor activity.

Tortajada A, Montes T, Martínez-Barricarte R, Morgan BP, Harris CL, de Córdoba SR.

Hum Mol Genet. 2009 Sep 15;18(18):3452-61. doi: 10.1093/hmg/ddp289. Epub 2009 Jun 23.

20.

Characterization of an NF-kappaB-regulated, miRNA-146a-mediated down-regulation of complement factor H (CFH) in metal-sulfate-stressed human brain cells.

Pogue AI, Li YY, Cui JG, Zhao Y, Kruck TP, Percy ME, Tarr MA, Lukiw WJ.

J Inorg Biochem. 2009 Nov;103(11):1591-5. doi: 10.1016/j.jinorgbio.2009.05.012. Epub 2009 May 24.

PMID:
19540598

Supplemental Content

Support Center